TY  - JOUR
A1  - Verma, Nidhi
A1  - Rai, Amit Kumar
A1  - Kaushik, Vibha
A1  - Brünnert, Daniela
A1  - Chahar, Kirti Raj
A1  - Pandey, Janmejay
A1  - Goyal, Pankaj
T1  - Identification of gefitinib off-targets using a structure-based systems biology approach; their validation with reverse docking and retrospective data mining
JF  - Scientific Reports
N2  - Gefitinib, an EGFR tyrosine kinase inhibitor, is used as FDA approved drug in breast cancer and non-small cell lung cancer treatment. However, this drug has certain side effects and complications for which the underlying molecular mechanisms are not well understood. By systems biology based in silico analysis, we identified off-targets of gefitinib that might explain side effects of this drugs. The crystal structure of EGFR-gefitinib complex was used for binding pocket similarity searches on a druggable proteome database (Sc-PDB) by using IsoMIF Finder. The top 128 hits of putative off-targets were validated by reverse docking approach. The results showed that identified off-targets have efficient binding with gefitinib. The identified human specific off-targets were confirmed and further analyzed for their links with biological process and clinical disease pathways using retrospective studies and literature mining, respectively. Noticeably, many of the identified off-targets in this study were reported in previous high-throughput screenings. Interestingly, the present study reveals that gefitinib may have positive effects in reducing brain and bone metastasis, and may be useful in defining novel gefitinib based treatment regime. We propose that a system wide approach could be useful during new drug development and to minimize side effect of the prospective drug.
KW  - gefitinib
KW  - side effects
KW  - drug
KW  - off-targets
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-167621
VL  - 6
IS  - 33949
ER  - 
TY  - JOUR
A1  - Brünnert, Daniela
A1  - Seupel, Raina
A1  - Goyal, Pankaj
A1  - Bach, Matthias
A1  - Schraud, Heike
A1  - Kirner, Stefanie
A1  - Köster, Eva
A1  - Feineis, Doris
A1  - Bargou, Ralf C.
A1  - Schlosser, Andreas
A1  - Bringmann, Gerhard
A1  - Chatterjee, Manik
T1  - Ancistrocladinium A induces apoptosis in proteasome inhibitor-resistant multiple myeloma cells: a promising therapeutic agent candidate
JF  - Pharmaceuticals
N2  - The N,C-coupled naphthylisoquinoline alkaloid ancistrocladinium A belongs to a novel class of natural products with potent antiprotozoal activity. Its effects on tumor cells, however, have not yet been explored. We demonstrate the antitumor activity of ancistrocladinium A in multiple myeloma (MM), a yet incurable blood cancer that represents a model disease for adaptation to proteotoxic stress. Viability assays showed a potent apoptosis-inducing effect of ancistrocladinium A in MM cell lines, including those with proteasome inhibitor (PI) resistance, and in primary MM cells, but not in non-malignant blood cells. Concomitant treatment with the PI carfilzomib or the histone deacetylase inhibitor panobinostat strongly enhanced the ancistrocladinium A-induced apoptosis. Mass spectrometry with biotinylated ancistrocladinium A revealed significant enrichment of RNA-splicing-associated proteins. Affected RNA-splicing-associated pathways included genes involved in proteotoxic stress response, such as PSMB5-associated genes and the heat shock proteins HSP90 and HSP70. Furthermore, we found strong induction of ATF4 and the ATM/H2AX pathway, both of which are critically involved in the integrated cellular response following proteotoxic and oxidative stress. Taken together, our data indicate that ancistrocladinium A targets cellular stress regulation in MM and improves the therapeutic response to PIs or overcomes PI resistance, and thus may represent a promising potential therapeutic agent.
KW  - multiple myeloma
KW  - ancistrocladinium A
KW  - naphthylisoquinoline alkaloids
KW  - proteasome inhibitor resistance
KW  - RNA splicing
KW  - cellular stress response
KW  - proteasome subunit beta type-5 (PSMB5)
KW  - activating transcription factor 4 (ATF4)
KW  - ataxia teleagiectasia mutated (ATM)
KW  - H2A histone family member X (H2AX)
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-362887
SN  - 1424-8247
VL  - 16
IS  - 8
ER  -